Gossamer Bio, Inc.
GOSS
$2.46
-$0.07-2.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -88.01% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.01% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -88.01% | -- | -- | -- | -- |
| SG&A Expenses | 0.12% | -9.50% | 3.73% | -8.48% | -13.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.85% | 11.30% | 16.60% | 7.18% | -5.47% |
| Operating Income | -174.42% | 12.27% | 7.43% | 16.23% | 212.54% |
| Income Before Tax | -171.32% | 12.62% | 26.40% | 20.18% | 226.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -177.74% | 12.62% | 31.40% | 23.01% | 215.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -177.74% | 12.62% | 31.40% | 23.01% | 215.85% |
| EBIT | -174.42% | 12.27% | 7.43% | 16.23% | 212.54% |
| EBITDA | -174.06% | 11.74% | 7.01% | 15.96% | 214.22% |
| EPS Basic | -177.39% | 13.03% | -36.47% | 34.38% | 148.88% |
| Normalized Basic EPS | -170.94% | 13.01% | -102.65% | 31.94% | 153.31% |
| EPS Diluted | -178.38% | 13.03% | -36.47% | 34.38% | 148.20% |
| Normalized Diluted EPS | -174.82% | 13.01% | -102.65% | 31.94% | 150.54% |
| Average Basic Shares Outstanding | 0.47% | 0.48% | 0.53% | 17.35% | 137.01% |
| Average Diluted Shares Outstanding | -4.72% | 0.48% | 0.53% | 17.35% | 149.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |